Unlock instant, AI-driven research and patent intelligence for your innovation.

Targeted protein degradation c-met degradation agent and its preparation method and application

A protein degradation and degradation agent technology, applied in the field of medicine, can solve the problems of acquired drug resistance of c-Met small molecule inhibitors, achieve significant proliferation inhibitory activity, good cell selectivity, and improve cell selectivity

Active Publication Date: 2021-09-28
SUZHOU UNIV
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] The main content of the present invention is aimed at the problem of acquired drug resistance of c-Met small molecule inhibitors, providing a c-Met degrader based on the strategy of targeting protein degradation PROTAC and its preparation method and application, as well as the c-Met degrader Application of Met degradation agent in the treatment of cancers such as non-small cell lung cancer and gastric cancer

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Targeted protein degradation c-met degradation agent and its preparation method and application
  • Targeted protein degradation c-met degradation agent and its preparation method and application
  • Targeted protein degradation c-met degradation agent and its preparation method and application

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0044]Example 1: Preparation of 2-(4-(4-(2-fluoro-4-(1-(((4-fluorophenyl)carbamoyl)cyclopropane-1-carboxamido)phenoxy)- 1,6-naphthyridin-7-yl)-1H-pyrazol-1-yl)acetic acid

[0045]

[0046] In the above reaction scheme, the reagents and conditions used are as follows: a) 2-(7-azabenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate, N, N-diisopropylethylamine, N,N-dimethylformamide; b) hydrogen, 10% wet palladium carbon, ethanol; c) cesium carbonate, N,N-dimethylformamide, 110 ° C; d ) Tetrakis(triphenylphosphine) palladium, cesium carbonate, 1,4-dioxane:water (5:1), 120°C; e) tert-butyl bromoacetate, potassium carbonate, N,N-dimethyl Formamide; f) trifluoroacetic acid, dichloromethane. The reaction steps are as follows:

[0047] Step 1: N-(4-(Benzyloxy)-3-fluorophenyl)-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide

[0048]

[0049] Dissolve 1-((4-fluorophenyl)carbamoyl)cyclopropane-1-carboxylic acid (2.9g, 13mmol), 4-(benzyloxy)-3-fluoroaniline (2.82g, 1...

Embodiment 2

[0065] Example 2: Preparation of 2-((2-(2,6-dioxaperidin-3-yl)-1,3-dioxoisoindoline-4-yl)oxy)acetic acid

[0066]

[0067] Reagents and conditions: a) pyridine, 3-amino-2,6-piperidinedione hydrochloride, 110°C; b) tert-butyl bromoacetate, potassium carbonate, N,N-dimethylformamide; c) Trifluoroacetic acid, dichloromethane.

[0068] Step 1: 2-(2,6-dioxopiperidin-3-yl)-4-hydroxyisoindoline-1,3-dione

[0069]

[0070] 4-Hydroxyisobenzofuran-1,3-dione (952mg, 5.84mmol) was dissolved in 10mL of pyridine, and 3-amino-2,6-piperidinedione hydrochloride (960mg, 5.84mmol) was added to react The solution was heated to 110°C and stirred overnight. After the reaction was completed, it was cooled to room temperature, pyridine was distilled off under reduced pressure, and the residue was purified by column chromatography (dichloromethane:methanol=100:1 to 100:3) to obtain a white solid (1.5 g, yield 93%). 1 H NMR (400MHz, DMSO-d 6 )δ11.20(s, 1H), 11.11(s, 1H), 7.66(t, J=7.8Hz, 1H), 7...

Embodiment 3

[0078]

[0079] Reagents and conditions: a) 2-(7-azabenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate, N,N-diisopropylethylamine, N,N-Dimethylformamide; b) trifluoroacetic acid, dichloromethane; c) 2-(7-azabenzotriazole)-N,N,N',N'-tetramethylurea Hexafluorophosphate, N,N-Diisopropylethylamine, N,N-Dimethylformamide.

[0080] Step 1: tert-butyl(2-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolyl-4-yl)oxy) Acetylamino) ethyl) carbamate

[0081]

[0082] 2-((2-(2,6-dioxapiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)acetic acid (1eq), (2-amino Ethyl) tert-butyl carbamate (1.2eq) was dissolved in 2mL N,N-dimethylformamide, and N,N-diisopropylethylamine (3eq) and 2-(7-aza Benzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate (1.1eq), continue to stir for 1 hour, after the reaction is complete, add 50mL ethyl acetate to dilute, ethyl acetate The phase was washed by adding saturated aqueous sodium bicarbonate solution (50mL*3), and washed by saturat...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a targeted protein degradation c-Met degradation agent as well as its preparation method and application. The invention provides a c-Met degrader based on the strategy of targeting protein degradation PROTAC and a preparation method thereof, as well as the application of the c-Met degrader in the treatment of cancers such as non-small cell lung cancer and gastric cancer. The compound of the present invention has significant c-Met degradation and cell proliferation inhibition, and has the potential to treat tumors as an anti-tumor drug, and the compound of the present invention shows significant Proliferation inhibitory activity, and significantly better than the small molecule inhibitor LXM-262, and significantly improved cell selectivity, illustrating that the example compounds of the present invention have significant advantages in overcoming tumor c-Met acquired drug resistance, especially the compound S27 only showed good activity on c-Met-dependent EBC-1 lung cancer cells, indicating that compound S27 has good cell selectivity, while the original small molecule inhibitor is multi-target and independent of c-Met The cell line also had an inhibitory effect.

Description

technical field [0001] The invention relates to a targeted protein degradation c-Met degradation agent and its preparation method and application, belonging to the technical field of medicine. Background technique [0002] c-Met, also known as hepatocyte growth factor (HGF) receptor, belongs to the family of receptor tyrosine kinases (RTKs). The combination of HGF and c-Met can regulate a variety of downstream signaling pathways to participate in a variety of physiological processes, including cell proliferation and survival, apoptosis and angiogenesis; when the HGF / c-Met signaling pathway is abnormal, it will lead to tumors happened. Furthermore, overexpression of the c-Met signaling pathway is associated with clinically poorer outcomes and resistance to EGFR inhibitors. Crizotinib and Cabozantinib are two small-molecule inhibitors of c-Met that are currently on the market. They are effective in clinical tumor treatment, but both face the problem of reduced curative effec...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C07D471/04C07D401/04C07D401/12C07K5/062C07K5/097C07K5/103A61K45/06A61K31/4545A61K31/454A61K38/05A61K38/06A61K38/07A61P35/00A61P35/02
CPCC07D471/04C07D401/04C07D401/12A61P35/00A61P35/02C07K5/0821C07K5/1013C07K5/06034
Inventor 龙亚秋王旭封顺
Owner SUZHOU UNIV